skip to content
Sphere fluidics : accelerating drug discovery Preview this item
ClosePreview this item
Checking...

Sphere fluidics : accelerating drug discovery

Author: Nektarios Oraiopoulos; Rebecca Goldberg
Publisher: London : University of Cambridge, Judge Business School, 2017.
Series: SAGE Knowledge., Cases.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Sphere Fluidics (SF), a University of Cambridge spinoff developed a technology for evaluating individual cells, called "single-cell analysis." The technology could very efficiently measure subtle differences in, for example, many different cancer cell subpopulations in a single biopsy. This simplified and streamlined the selection process for identifying important unique cells with potential benefits for healing  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Named Person: Frank Craig
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Nektarios Oraiopoulos; Rebecca Goldberg
ISBN: 9781526444417 1526444410
OCLC Number: 1023532052
Notes: Originally published in Oraiopoulos, N., & Goldberg, R. (2017). Sphere Fluidics: Accelerating drug discovery. Cambridge, UK: University of Cambridge, Judge Business School.
Description: 1 online resource : illustrations.
Series Title: SAGE Knowledge., Cases.
Responsibility: Nektarios Oraiopoulos, Rebecca Goldberg.

Abstract:

Sphere Fluidics (SF), a University of Cambridge spinoff developed a technology for evaluating individual cells, called "single-cell analysis." The technology could very efficiently measure subtle differences in, for example, many different cancer cell subpopulations in a single biopsy. This simplified and streamlined the selection process for identifying important unique cells with potential benefits for healing difficult diseases such as various types of cancer. Despite SF's revolutionary technology, developing a viable go-to-market strategy was daunting. Becoming a product-based company required overcoming new challenges and carefully working with internal and external stakeholders. Under the leadership of Frank Craig, CEO of SF, the company had worked successfully with key partner companies to develop prototype versions of the product for its first customers. The case examines the commercialization roadmap of SF and the decisions that Craig had to make to convert the original technology to a product that has gained considerable market traction. Now, Craig has to identify (and justify to SF's board) the most promising market segments that would allow SF to scale up its production and establish its position as a key supplier in the highly diversified life sciences R&D landscape.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1023532052> # Sphere fluidics : accelerating drug discovery
    a schema:CreativeWork, schema:Book, schema:MediaObject ;
    library:oclcnum "1023532052" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/enk> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/4769049847#Organization/sphere_fluidics> ; # Sphere Fluidics.
    schema:about <http://experiment.worldcat.org/entity/work/data/4769049847#Topic/business_planning> ; # Business planning
    schema:about <http://experiment.worldcat.org/entity/work/data/4769049847#Topic/new_business_enterprises> ; # New business enterprises
    schema:about <http://experiment.worldcat.org/entity/work/data/4769049847#Person/craig_frank_active_2017> ; # Frank Craig
    schema:about <http://dewey.info/class/658.11/e23/> ;
    schema:author <http://experiment.worldcat.org/entity/work/data/4769049847#Person/oraiopoulos_nektarios> ; # Nektarios Oraiopoulos
    schema:author <http://experiment.worldcat.org/entity/work/data/4769049847#Person/goldberg_rebecca_active_2017> ; # Rebecca Goldberg
    schema:bookFormat schema:EBook ;
    schema:datePublished "2017" ;
    schema:description "Sphere Fluidics (SF), a University of Cambridge spinoff developed a technology for evaluating individual cells, called "single-cell analysis." The technology could very efficiently measure subtle differences in, for example, many different cancer cell subpopulations in a single biopsy. This simplified and streamlined the selection process for identifying important unique cells with potential benefits for healing difficult diseases such as various types of cancer. Despite SF's revolutionary technology, developing a viable go-to-market strategy was daunting. Becoming a product-based company required overcoming new challenges and carefully working with internal and external stakeholders. Under the leadership of Frank Craig, CEO of SF, the company had worked successfully with key partner companies to develop prototype versions of the product for its first customers. The case examines the commercialization roadmap of SF and the decisions that Craig had to make to convert the original technology to a product that has gained considerable market traction. Now, Craig has to identify (and justify to SF's board) the most promising market segments that would allow SF to scale up its production and establish its position as a key supplier in the highly diversified life sciences R&D landscape."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/4769049847> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/4769049847#Series/sage_knowledge_cases> ; # SAGE Knowledge. Cases
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/4769049847#Series/sage_knowledge> ; # SAGE Knowledge.
    schema:name "Sphere fluidics : accelerating drug discovery"@en ;
    schema:productID "1023532052" ;
    schema:url <http://sk.sagepub.com/cases/sphere-fluidics-accelerating-drug-discovery> ;
    schema:workExample <http://worldcat.org/isbn/9781526444417> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1023532052> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/4769049847#Person/goldberg_rebecca_active_2017> # Rebecca Goldberg
    a schema:Person ;
    schema:familyName "Goldberg" ;
    schema:givenName "Rebecca" ;
    schema:name "Rebecca Goldberg" ;
    .

<http://experiment.worldcat.org/entity/work/data/4769049847#Person/oraiopoulos_nektarios> # Nektarios Oraiopoulos
    a schema:Person ;
    schema:familyName "Oraiopoulos" ;
    schema:givenName "Nektarios" ;
    schema:name "Nektarios Oraiopoulos" ;
    .

<http://experiment.worldcat.org/entity/work/data/4769049847#Series/sage_knowledge> # SAGE Knowledge.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1023532052> ; # Sphere fluidics : accelerating drug discovery
    schema:name "SAGE Knowledge." ;
    .

<http://experiment.worldcat.org/entity/work/data/4769049847#Series/sage_knowledge_cases> # SAGE Knowledge. Cases
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1023532052> ; # Sphere fluidics : accelerating drug discovery
    schema:name "SAGE Knowledge. Cases" ;
    .

<http://experiment.worldcat.org/entity/work/data/4769049847#Topic/business_planning> # Business planning
    a schema:Intangible ;
    schema:name "Business planning"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/4769049847#Topic/new_business_enterprises> # New business enterprises
    a schema:Intangible ;
    schema:name "New business enterprises"@en ;
    .

<http://worldcat.org/isbn/9781526444417>
    a schema:ProductModel ;
    schema:isbn "1526444410" ;
    schema:isbn "9781526444417" ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.